April 2 (Reuters) - Roivant Sciences' (ROIV.O), opens new tab experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study, sending the biotech firm's shares up nearly 8% on Tuesday.
Roivant Sciences` lupus drug fails to reduce symptoms in mid-stage study
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today reported its financial results for the first quarter ended June 30, 2022 and provided an update on the Company’s operations.